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Background. The use of 2-[18F]ﬂuoro-2-deoxy-D-glucose ([18F]FDG) may help to establish the antitumor activity of enzastaurin,
a novel protein kinase C-beta II (PKC-βII) inhibitor, in mouse xenografts. Methods. The hematologic cell line RAJI and the solid
tumor cell line U87MG were each implanted in NOD/SCID mice. Standard tumor growth measurements and [18F]FDG PET
imaging were performed weekly for up to three weeks after tumor implantation and growth. Results. Concomitant with caliper
measurements, [18F]FDG PETimaging was performed to monitor glucose metabolism. Heterogeneity of glucose uptake in various
areas of the tumors was observed after vehicle or enzastaurin treatment. This heterogeneity may limit the use of [18F]FDG PET
imaging to measure enzastaurin-associated changes in xenograft tumors. Conclusion.[ 18F]FDG PET imaging technique does not
correlate with standard caliper assessments in xenografts to assess the antitumor activity of enzastaurin. Future studies are needed
to determine the use of [18F]FDG PET imaging in preclinical models.
Copyright © 2009 Karen E. Pollok et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Imaging techniques play an important role in the diagnosis,
staging, and follow-up of cancer patients. While standard
imaging techniques, such as computed tomography (CT),
are based on diﬀerences in the anatomical structure of the
tissues, positron emission tomography (PET) uses radiola-
beled molecular probes to assess diﬀerences in biological or
biochemical properties of tissues [1]. The most commonly
used tracer for PET is the glucose analogue 2-[18F]ﬂuoro-
2-deoxy-D-glucose ([18F]FDG), which provides an estimate
of tissue glucose utilization. Today, [18F]FDG PET is widely
used in clinical diagnoses of cancer, including lung cancer
[2], non-Hodgkin lymphoma [3], and glioblastoma [4].
Because of this increased utility in oncology [5–7], [18F]FDG
PET is being evaluated as a tool to assess antitumor eﬀects of
standard or novel anticancer drugs in both human subjects
and in animal models of cancer [8]. PET imaging may
provide evidence of biological responses of novel anticancer
compounds, which, in turn, can facilitate the transition of
compounds from preclinical to clinical investigation. One
such novel compound is enzastaurin, which was developed
as a Protein kinase C-beta (PKC-β) inhibitor.
The family of Protein Kinase C (PKC) has been impli-
cated in processes that control tumor growth, survival, and
progression [9]. In particular, PKC-β activation has been2 Journal of Oncology
recognized as an important contributor to malignant growth
indiﬀuselargecellBcelllymphoma[10]andinglioblastoma
[11]. Recently, enzastaurin has shown antitumor activity in
xenograft models of the colorectal cancer cell line HCT116
and in the glioblastoma cell line U87MG [12]. While
enzastaurin was designed as a selective PKC-β inhibitor,
recentstudiessuggestthatitsantitumoractivityismodulated
by activation of GSK-3β and the PI3K/AKT pathway [12]. In
this study we evaluated the extent to which [18F]FDG PET
imaging can accurately characterize the antitumor activity of
enzastaurin in two diﬀerent mouse xenograft tumor models.
2.MaterialandMethods
2.1. Animal Model. Nonobese diabetic/severe combined
immunodeﬁcient (NOD/SCID) mice were raised and cared
for by the Indiana University Simon Cancer Center Trans-
plant and Xenograft Core following the institutional guide-
lines of animal care. The study was conducted from October
2004 to July 2005.
2.2. Cell Lines. The glioblastoma cell line, U87MG, and
Burkitt’s lymphoma cell line, RAJI, were obtained from the
American Type Culture Collection (ATCC, Manassas, Va,
USA) and cultured as recommended by ATCC. As previously
published,U87MGandRAJIcellsexpresshighlevelsofPKC-
β [12, 13].
2.3. Xenograft Tumor Studies. Prior to subcutaneous (s.c.)
injection, cells were resuspended in a 1 : 1 ratio of tumor
cells : matrigel (BD Biosciences, Bedford, Mass, USA) and
Burkitt’s lymphoma cell line, RAJI was resuspended in a 1 : 2
ratio of tumor cells : matrigel. Each mouse was injected s.c.
in the right ﬂank with 5 × 106 cells. Mice were monitored
daily for palpable tumors.
2.4. Enzastaurin Administration. Enzastaurin treatment was
initiated when the tumors reached a volume of at least
150mm3. Mice with similar tumor sizes were matched in
the control and enzastaurin treated groups. Enzastaurin was
suspended in 10% acacia (Fisher Scientiﬁc, Fair Lawn, NJ,
USA) in water and dosed by gavage twice daily at 75mg/kg
based upon weekly body measurements for each treated
group. Control groups were treated only with vehicle.
2.5. PET and CT Imaging. Each animal was anesthetized
withacepromazine(1-2mg/kgi.m.)andtorbugesic(2mg/kg
i.m.) and placed on a custom bed for imaging. Animals
were administered 0.5–1mCi of [18F]FDG via a tail vein
injection.Astatic15-minutePETstudywasperformedusing
the IndyPET II scanner [14, 15] at 45 minutes posttracer
injection. Following the PET study, the animal bed was
moved to and mounted on an EVS RS9 microCT scanner,
and a volumetric image that encompassed the tumor volume
was imaged at approximately 90 micron spatial resolution.
FDG Utilization Estimates. FDG uptake estimates are gen-
erated by placing ROIs on PET images acquired over the
time period from 45–60 minutes posttracer administration.
Indices of tumor FDG uptake were generated by calculating
a ratio of the tumor to muscle uptake and by calculating the
standardized uptake value (SUV):
SUVFDG =
 60
45Ct(t)dt


ρ × ID

/M
. (1)
In (1) Ct(t) is the concentration of [F-18] in the tumor
from the PET image, M is the mass of the animal, ID is the
dose of the tracer injected into the animal, and ρ is tissue
density. [18F]FDG was prepared by the Hamacher method
using a commercial synthesis unit provided by PETNET/CTI
(Knoxville, Tenn, USA) [16].
2.6. Statistical Analyses. Endpoints included tumor volume
via calipers, tumor volume via CT, PET-determined mea-
sures for tumor, muscle, tumor/muscle ratio, and a stan-
dardized measure of uptake. Changes from baseline for each
endpoint were analyzed for each cell line (U87MG, RAJI)
and each time point (Week 2, Week 3) using nonparametric
statistical methods (Wilcoxon rank-sum test) to compare
treatedversuscontrolanimals.Due totheexploratory nature
of the analyses, P-values were used to indicate trends and
potential future research hypotheses, rather than to test and
conﬁrm prespeciﬁed hypotheses.
3. Results
We ﬁrst investigated whether two tumor cell lines provided
acceptable tumor growth in NOD/SCID mice to allow
reproducible imaging with [18F]FDG PET (Figure 1). We
used U87MG cells as a representative cell line for solid
tumors, and RAJI as a model for hematologic cancers. Both
the U87MG (Figure 1(a)) and the RAJI (data not shown)
tumor types grew consistently in NOD/SCID mice prior to
drug treatment and [18F]FDG PET imaging reliably detected
glucose uptake in xenografts as determined by Standardized
Uptake Value (SUV) (see Materials and Methods). In these
feasibility studies, we also found that SUV correlated with
U87MG tumor size as measured by CT (Figure 1(b)).
Based on these preliminary observations of initial tumor
growth, we elected to use both tumor cell lines to evalu-
ate enzastaurin-induced metabolic changes as detected by
[18F]FDG uptake.
Enzastaurin-induced metabolic changes were evaluated
using [18F]FDG uptake in two independent experiments
for each tumor cell line, U87MG and RAJI, respectively
(Table 1). Consistent with previous studies in nude mice
[12],enzastaurininducedtumorgrowthdelayinNOD/SCID
mice implanted with U87MG and RAJI (Figures 2(a) and
2(b)). U87MG cells grew slower than RAJI cells, and
enzastaurin had a tumor growth delay mainly in the U87MG
tumor cell model (Figures 2(a) and 2(b)). A signiﬁcant
tumorgrowthdelaywasseeninU87MGaftertreatmentwith
enzastaurin over the period of 3 weeks (Figure 2(a)). In the
RAJI xenograft model, there was a trendin the tumor growth
delay, but not a statistically signiﬁcant diﬀerence betweenJournal of Oncology 3
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Figure 1: Correlation of Standard Caliper Measurements to FDG-PET uptake measured by SUV (Panel (a)) and Correlation of SUV with CT-
basedTumorSize(Panel(b)):U87MGxenografttumorcellgrowthwasassessedoveraperiodof3weeksusingstandardcalipermeasurements
(mm3), serial FDG-PET uptake, and tumor size by CT scan (see Material and Methods). Correlation between the three diﬀerent tumor
growth measurements was plotted after 2 weeks (open symbols) and after 3 weeks (closed symbols) of tumor growth. Correlation between
standard caliper measurements and standardized uptake value (SUV) was plotted (Panel (a)), and SUV was correlated with tumor size
determined by CT scan (Panel (b)) (correlation coeﬃcient 0.8, P = .001). (Correlation excludes one mouse with necrotic intratumoral
tissue at Week 3 indicated by .)
vehicle and enzastaurin-treated groups (Figure 2(b)). Con-
comitant with caliper measurements, [18F]FDG PET was
performed.[18F]FDGPETimagingwasevaluatedusingSUV
(Figures 2(c) and 2(d)) and tumor/muscle ratio (Figures
2(e) and 2(f)). Enzastaurin administration did not alter
tumor glucose metabolism as measured by SUV changes
in U87MG xenografts (Figure 2(c)). Compared to RAJI,
the SUV changes in U87MG xenografts occurred at smaller
signal intensities, and thus contributed to an overlap of SUV
measurements between vehicle- and enzastaurin-treated
mice (compare Figures 2(c) and 2(d)). In RAJI, SUV uptake
appeared to be increased at weeks 2 and 3 in enzastaurin-
treated compared to vehicle-treated mice (P<. 10 at
weeks 2 and 3; Figure 2(d)). It is possible that metabolic
heterogeneity of the tumor glucose metabolism in diﬀerent
areas of the tumor may have caused this diﬀerence in SUV
uptake. In addition to SUV, we also used tumor/muscle
ratio to determine the metabolic eﬀect of enzastaurin in
tumors. The tumor/muscle ratio uses muscle tissue with its
low metabolic rate to normalize the tumor tissue [18F]FDG
uptake. Based on this analysis there was no clear evidence
of a metabolic change induced by enzastaurin compared
to vehicle treatment (Figures 2(e) and 2(f)). However, for
U87MG there was a trend in FDG uptake in enzastaurin-
treated mice (P<. 10 at week 3), which was not observed
in RAJI xenografts (Figures 2(e) and 2(f),r e s p . ) .N e x t ,w e
determined tumor volume by using standard volumetric
measurements based on CT. After enzastaurin treatment,
we observed a trend in tumor size reduction for RAJI
xenograftsbutnotforU87MGxenograftsatweek2(P<. 10)
(Figures 2(g) and 2(h)). While the collective analysis of all
animals from 2 independent experiments did not reveal a
clear distinction between enzastaurin- and vehicle-treated
animals, there were some animals that did show a metabolic
change after enzastaurin treatment. In these cases we saw a
decline only after two weeks of treatment that was essentially
undetectable after the third week of treatment (Figures
3(a)–3(f) and Figures 4(a)–4(f)). The changes observed in
U87MG were diﬀerent from changes observed in RAJI. In
U87MG xenografts, [18F]FDG uptake declined after the 2nd
week of treatment. The RAJI tumors were fast growing and
had large areas of necrotic tissue and some areas with newly
increased [18F]FDG uptake (Figure 5) .T h eg r o w t hp a t t e r n
of these tumors is partly responsible for the intertumoral
heterogeneity seen in this study and may contribute to the
lack of detecting enzastaurin-induced changes in the tumor.
4. Discussion
In this study we used a specialized PET imaging approach
which was developed to assess activity of anti-cancer agents
in small animals [14]. Changes in [18F]FDG uptake were
generally found to correlate with reduction in tumor size
as determined by caliper measurements [17, 18]. Our
study uses a metabolic kinase inhibitor to compare drug-
mediatedtumorgrowthreductionwithmetabolicalterations
invivo.Whilepreviousimagingstudiesevaluatedanti-tumor
activity of cytotoxic agents, it is not clear how [18F]FDG
PETimagingcanhelpdetermineantitumoractivityofkinase4 Journal of Oncology
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Figure 2: Tumor assessments of Xenografts U87MG and RAJI at 2 and 3 weeks after enzastaurin treatment. Standard caliper measurements
show a tumor growth delay for U87MG (P<. 05 at week 3), but not for RAJI (Panels (a) and (b)). [18F]FDG-PET imaging was performed
at the same time as standard caliper measurements (Panels (c)-(d)). Tumor glucose metabolism changes were measured by SUV (Panels (c),
(d)) and tumor/muscle ratio (Panels (e), (f)) in U87MG and RAJI xenografts. Only in RAJI xenografts enzastaurin treatment showed a trend
in increased SUV (Panel (d); P<. 10 at weeks 2 and 3). Using tumor/muscle ratio indicated a trend for FDG uptake in U87MG (P<. 10
at week 3) (Panel (e)), but not in RAJI xenografts (Panel (f)). The tumor size assessment based on CT scan (Panels (g) and (h)) indicated
a trend for detecting reduced tumor size only in RAJI xenografts after enzastaurin treatment at week 2 (P<. 10). Mice treated with vehicle
alone are shown in green; mice treated with enzastaurin are shown in red, representation of 2 independent experiments.
Table 1: Evaluable sample sizes for caliper measures (CT/PET measures in parentheses).
U87MG (n)R A J I ( n)
Week Enzastaurin Vehicle Enzastaurin Vehicle
2 19 (12) 15 (8) 7 (7) 7 (5)
3 15 (11) 12 (6) 7 (7) 6 (4)Journal of Oncology 5
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Figure 3:SUVinNOD/SCIDmiceimplantedwithU87MG.Representativemousetreatedwithvehicle(Panel(a)–(c))andenzastaurin(Panel
(d)–(f)) at baseline ((a),(d)) and after 2 weeks ((b), (e)) and 3 weeks ((c), (f)) of treatment. Green circle represents the region of interest
(ROI)toassesschangesinFDGuptake.PicturesareafusedimageoftheCTandPET.Eachpanelcontainsthecalipermeasurements(bottom
right).
inhibitors. For instance, imatinib activity was evaluated in
mice with limited success [19]. In addition to its cost, the use
of PET imaging may be limited due to the spatial resolution
of current PET scanners [20]. Thus, few studies have been
published which evaluate the use of small animal imaging in
drug discovery.
For the ﬁrst time, we assessed the anti-tumor activity
of the serine/threonine kinase inhibitor enzastaurin by
[18F]FDG uptake in mice. Because we used NOD/SCID
instead of conventional nude mice, we ﬁrst conﬁrmed that
[18F]FDG PET images could reproducibly be obtained in
xenografts of glioblastoma and lymphoma. This feasibility
assessment was important to establish the tumor size at
which [18F]FDG uptake is detectable in mice. Tumors had
to be at least 150mm3 in volume to be visualized by the
scanner, and the best assessment was observed in tumors
that were more than 400mm3 (Figure 1). This is consistent
with other studies which reported on the need of speciﬁc
tumor sizes for scanner assessment [21]. The subsequent
studies with enzastaurin treatment did not provide clear
evidence of enzastaurin-induced metabolic changes in either
of the two tumor types examined. However, there are
several possibilities why enzastaurin-induced changes were
not detected by [18F]FDG PET imaging.
First, it is possible that enzastaurin may not have a
homogenous impact on the metabolic rate in the tumor
tissue. Although PKC isoenzymes have been implicated
in cell proliferation [9], their speciﬁc role during glucose
metabolism is still not understood. On one hand, glucose
can induce PKC-β expression [22], and on the other hand,
overexpressionofPKC-β reducesglucoseuptakeincells[23].
Hence, selective PKC-β inhibitors have been investigated
as potential treatments for diabetes [24]. Whether such a
PKC-β-dependent glucose regulation exists in tumor cells6 Journal of Oncology
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Figure 4: SUV in NOD/SCID mice implanted with RAJI. Representative mouse treated with vehicle (Panel (a)–(c)) and enzastaurin (Panel
(d)–(f)) at baseline ((a), (d)) and after 2 weeks ((b), (e)) and 3 weeks ((c), (f)) of treatment. Green circle represents the region of interest
(ROI)toassesschangesinFDGuptake.PicturesareafusedimageoftheCTandPET.Eachpanelcontainsthecalipermeasurements(bottom
right).
is not known [25]. Considering the observation of this
study, in which tumor growth delay and glucose metabolism
are not correlated with enzastaurin activity in xenograft
tumors, it is possible that enzastaurin is not able to modulate
the complex glucose regulation in the tumor cells [26].
Recently, the antiangiogenic kinase inhibitor AZD2171 was
also evaluated in a small animal study for its metabolic
change in tumors. Compared to [18F]FDG PET imaging,
only [18F] ﬂuoromethane proved as a useful tool to assess the
anti-tumor activity of AZD2171 [27]. Therefore, it appears
that only some kinase inhibitors will have metabolic changes
in tumors, which can be assessed by [18F]FDG PET imaging.
Secondly, the s.c. implanted tumors tend to grow initially
along the skin surface and inﬁltrate the underlying tissue to
a lesser extent. This observation might explain why perhaps
the caliper measurements can be used to demonstrate
anti-tumor eﬀects while the imaging of the deeper tissue
by [18F]FDG or CT is not able to detect diﬀerences of
treatment eﬀect. Because of the inability to delineate clearly
the borders of the inﬁltrating tumor tissue, the current
study may underestimate the metabolic change and thus
lead to false-negative imaging results. In some animals,
we used contrast dye to delineate better the tumor border
in mice. In these instances, caliper and CT scans showed
comparable results. Hence, future studies will need to be
conducted with contrast imaging techniques to approximate
the anatomical borders of the tumor. Tumor weight did not
correlate with caliper measurements, because CT scans or
caliper measurements were taken during the course of the
study,whiletumorweightwascollectedonlyattheendoftheJournal of Oncology 7
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Figure 5: SUV in NOD/SCID mice implanted with RAJI. Representative 3 mice treated with enzastaurin for 3 weeks (Panel (a)–(c)). Green
circle represents the region of interest (ROI) to assess changes in FDG uptake. Pictures are a fused image of the CT and PET. Each panel
contains the caliper measurements (bottom right).
study,whenanimalsweresacriﬁced,andtumorshadbecome
heterogeneous.
Finally, the observed [18F]FDG uptake signals are con-
siderably lower relative to what is measured in humans. The
low baseline level in the present xenograft study negatively
impacted the ability to assess early changes in metabolism
associated with treatment eﬀect. Other factors inﬂuencing
the low uptake signal are heterogeneity of glucose uptake
in tumors, possible emergence of drug-resistant tumor cells,
variability of pharmacokinetic exposure of the inhibitor, and
the diﬀusion of tracer to the tumor site.
In summary, our data are consistent with the hypothesis
thatshrinkingtumorsize(assessedbycalipermeasurements)
doesnotequatetoreductioninoveralltumormetabolism.In
fact, “pockets” of drug-resistant tumor cells with increased
glucose uptake and growth kinetics may become prevalent in
certain areas of the tumor, while glucose reduction will be
present in other areas. Additional longitudinal PET imaging
studies will have to examine in detail the variables which
aﬀect the accurate measurement of tumor response to drug
treatment. Our study implies that [18F]FDG PET imaging
will be useful only in a select type of tumors and perhaps
detect antitumor activity only for a limited number of
drugs.
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